Brain imaging tool falls short for human tissue
Imperial academics respond to government net zero announcements
Imperial startups pitch to investors at London Demo Day
CDDS researchers work across a wide range of diseases, from infection and inflammation to oncology, cardiovascular disease and neurodegeneration.
View our network of disease experts
The CDDS brings together expertise in new screening technologies, target deconvolution, ultrasensitive biomarker analysis, microfluidic devices, and more.
View technology areas
We are developing small molecule, peptide, biological and cell-based modalities across a wide range of target classes and novel modes of action.
View target classes
